利培酮和奎硫平治疗首发精神分裂症对照研究

Comparative study between the effect of Risperdal and quetiapine in first-episode schizo phrenia

目的:比较利培酮和奎硫平治疗首发精神分裂症的疗效和安全性。方法:将80例符合中国精神障碍分类与诊断标准第3版诊断标准的首发精神分裂症患者,随机平分为利培酮组和奎硫平组各40例,疗程6周。采用阳性与阴性症状量表(PANSS)、副反应量表(TESS)评定疗效与不良反应。结果:利培酮组阳性症状评分下降显著大于奎硫平组;两组阴性症状、一般精神病理症状和PANSS总分下降差异无显著性(P>0.05)。利培酮组主要不良反应为体质量(体重)增加、肝功能损害和锥体外系症状;奎硫平组主要不良反应为嗜睡和头昏。结论:维思通对精神分裂症阳性症状的疗效优于奎硫平,两药不良反应均相对较轻。

Objective： To compare the efficacy and safety of risperdal and quetiapine in the treatment of first - episode schizophrenia. Methods：80 patients with first -episode schizophrenia （according to Chinese classification of mental disorders, third edition） were divided into two groups who treated with risperdal or quetiapine respectively for 6 weeks. The positive and negative syndrome scale（PANSS） and treatment emergent side effect scale （TESS） were used to evaluate efficacy and adverse effect before and after treatment respectively. Results ： The scores of positive syndrome of PANSS in risperdal group was significantly lower than quetiapine group at 6 week after trentment. There was no significant differences in the scores of negative syndrome scale, general and total scale of PANSS between two groups. The most adverse effects of risperdal were weight gain, liver dysfunction and extrapyramidal side effects. The most adverse effects of quetiapine were drowsiness and dizzy. Conclusions： The efficacy on positive syndrome of risperdal is better than that of quetiapine , and they both have fewer side effects.